All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2017-09-21T09:28:27.000Z

ASCO-SITC Clinical Immuno-Oncology Symposium: abstract submission deadline 3rd October

Sep 21, 2017
Share:

Bookmark this article

The next ASCO-SITC Clinical Immuno-Oncology Symposium will take place in San Francisco, CA, USA from 25th–27th January 2018. Abstract submission is due to close on Tuesday 3rd October 2017, 11:59 pm EDT.

The deadline for Late-Breaking Abstract (LBA) submissions is Tuesday 21st November 2017 at 12:00 pm (noon) EDT; however, authors must submit a shell/placeholder abstract by October 3rd to be considered for LBA submission.

The symposium is described as “a three-day meeting focused on clinical and translational research in immune-oncology and the implications for clinical care” and aims to “address the high-level need for clinical education in a field where all aspects of care are fundamentally different from traditional therapies.” The program will offer insights into the use of immunotherapy in hematologic malignancies, as well as in melanoma, lung cancer, and solid tumors through a varied number of sessions including Keynote Lectures, early morning “Immunology 101” talks, “Networking Roundtable” opportunities, and “Evening Highlights” sessions.

Subcategories within the Hematologic Malignancies category include: biomarkers and inflammatory signatures, cell therapies, humoral immunity for diagnosis and therapy, immune checkpoints and stimulatory receptors, and modulating innate immunity.

For more information on abstract submission guidelines, visit: http://immunosym.org/abstracts/abstract-submission-guidelines

 

 

  1. ASCO-SITC. Clinical Immunology-Oncology Symposium.http://immunosym.org/. Accessed [2017 Sep 20].
More about...

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox